Ross\Johnson & Associates LLC Exelixis, Inc. Transaction History
Ross\Johnson & Associates LLC
- $5.83 Billion
- Q1 2025
A detailed history of Ross\Johnson & Associates LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Ross\Johnson & Associates LLC holds 40 shares of EXEL stock, worth $1,816. This represents 0.03% of its overall portfolio holdings.
Number of Shares
40Holding current value
$1,816% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding EXEL
# of Institutions
608Shares Held
256MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.52 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.3 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$1.02 Billion4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$673 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$535 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $14.6B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...